Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Caron A. Jacobson,Julio C. Chavez,Alison R. Sehgal,Basem M. William,Javier Munoz,Gilles Salles,Carla Casulo,Pashna N. Munshi,David G. Maloney,Sven de Vos,Ran Reshef,Lori A. Leslie,Ibrahim Yakoub-Agha,Olalekan O. Oluwole,Henry C. Fung,Vicki Plaks,Yin Yang,Jennifer L. Lee,Mauro P. Avanzi,Sattva S. Neelapu

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

2020

8008Background: Advanced stage iNHL, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), is considered incurable as most pts experience multiple relapses (Wang, et al. Ther Adv Hem...

Keywords:

Indolent Non-Hodgkin Lymphoma
Oncology
Internal medicine
Interim analysis
Pathology
Phases of clinical research
in patient
relapsed refractory
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations